The Afirma Genomic Sequencing Classifier (GSC) is a rule‐out test for malignancy/
noninvasive follicular thyroid neoplasms with papillary‐like nuclear features among patients …

Combined Afirma Genomic Sequencing Classifier and TERT promoter mutation detection in
molecular assessment of Bethesda III–VI thyroid nodules - Ladenson - 2023 - Cancer …

Introduction: The Afirma® Xpression Atlas (XA) detects gene variants and fusions in thyroid
nodule FNA samples from a curated panel of 511 genes using whole-transcriptome RNA …

Abstract Background The Afirma Genomic Sequencing Classifier uses whole transcriptome
RNA sequencing to identify thyroid nodules as benign or suspicious. The Afirma Xpression …

BACKGROUND Fine‐needle aspiration (FNA) cytology is a common approach to evaluating
thyroid nodules, although 20% to 30% of FNAs have indeterminate cytology, which hampers …

Recent analytical and clinical validation of the Afirma Xpression Atlas (XA) demonstrates test
reliability and the identification of genomic alterations that may inform patient management …

Importance Thyroid cancer incidence is increasing, and when fine-needle aspiration biopsy
results are cytologically indeterminate, the diagnosis is often still established only after …

Background: For thyroid nodules with indeterminate cytology, the Afirma Gene Expression
Classifier (GEC) identified benign nodules to reduce diagnostic surgery, though many …

The incidence of thyroid cancer is rising for a variety of reasons. At the same time, the
nomenclature revision of non-invasive encapsulated follicular-variant PTC to noninvasive …

Importance Use of next-generation sequencing of RNA and machine learning algorithms
can classify the risk of malignancy in cytologically indeterminate thyroid nodules to limit …